Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review

Owczarczyk-Saczonek A., Kasprowicz-Furmańczyk M., Kruszewska A., Krajewska-Włodarczyk M., Bechtold A., Klimek P.

Case Report / Series on Face & Skin, published in Dermatol Ther (Heidelb) (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Dermatol Ther (Heidelb) (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32876907
PMCID
PMC7649201
DOI
10.1007/s13555-020-00438-z
Citations
10

Abstract (original English)

Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients' quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation Juvéderm ® Voluma or Volux, Vycross ® technology, Allergan, injected. One of the patients had additionally fractional ablative CO 2 laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-L-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morph

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research